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Abstract
Background MicroRNAs (miRNAs, miRs) are involved in
most physiological, developmental, and pathological pro-
cesses. miR-192 and miR-205 are expressed preferentially
in the renal cortex and closely relevant to the renal cell
biology. In the present study, we aim to measure the serum
levels of miR-192 and miR-205 and their correlation with
clinicopathological data in patients with primary focal seg-
mental glomerulosclerosis (FSGS) and minimal change dis-
ease (MCD).
Methods Fifty-six patients (35 male, 21 female) with idio-
pathic nephrotic syndrome (FSGS 30, MCD 26) and 20
healthy controls were enrolled in the study. We quantified
the serum levels of miR-192 and miR-205 in patients with
FSGS and MCD by RT-qPCR.
Results Patients with FSGS had higher serum levels of miR-
192 and miR-205 than those with MCD (324.49±42.74
fmol/l versus 90.19±27.14 fmol/l, p<0.01, 2.25±0.69
fmol/l versus 0.60±0.51 fmol/l, p<0.01, respectively). The
level of miR-192 was positively correlated with the protein-
uria in patients with FSGS and MCD (r=0.62, p<0.001,
r=0.84, p<0.001, respectively). Similarly, the level of miR-
205 was positively correlated with the proteinuria in patients
with FSGS (r=0.54, p=0.002). In addition, the serum level
of miR-192 was significantly correlated with the degree of
interstitial fibrosis in patients with FSGS (r=0.342, p<0.05).
Conclusions miR-192 and miR-205 have the potential as
markers to differentiate FSGS from MCD.
Keywords Focal segmental glomerulosclerosis . Minimal
change disease . Nephrotic syndrome . miRNAs
Introduction
Primary focal segmental glomerulosclerosis (FSGS) and min-
imal change disease (MCD), lumped together as podocytop-
athy, are both characterized by heavy proteinuria and the
nephrotic syndrome (NS) as well as extensive flattening of
podocyte foot process in ultrastructural morphology [1]. How-
ever, FSGS often shows lesions as glomerulosclerosis, tubular
atrophy, and interstitial fibrosis, followed by therapeutic di-
lemma, steroid resistance, which shows a tendency to process
to end-stage renal disease (ESRD) [2, 3]. Currently, clinicians
predict the severity and prognosis of the idiopathic nephrotic
syndrome in children through their response to steroids, rather
than through kidney biopsy, which is the precise approach to
distinguish MCD from FSGS. The consequence of an impre-
cise diagnosis in these children is exposure to the high risk of
morbidity due to immunosuppression [4]. To our knowledge,
there has not been a reliable biomarker for FSGS and MCD.
MicroRNAs (miRNAs, miRs) appear to play roles in
most physiological, developmental, and pathological pro-
cesses. Many of the miRNAs can be found in extracellular
fluid such as plasma, serum [5, 6], and urine [7] in addition
to tissues and cells. miRNAs are relatively stable, which
makes them ideal as biomarkers for disease. Although plen-
ty of miRNAs are widely expressed in many tissues, some
miRNAs are found to be highly organ-specific [8]. miR-192
and miR-205 are expressed preferentially in the renal cortex
and closely relevant to the renal cell biology [9, 10]. miR-
192 and miR-205 are more abundant in the kidney than
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other organs(rat) [10]. Wang et al. [11] showed miR-192 and
miR-205 were found elevated in renal tissues of patients
with hypertensive glomerulosclerosis. In the present study,
we examine the serum levels of miR-192 and miR-205 and
their correlation with clinicopathological data.
Patients and methods
Patient cohort and blood collection
Fifty-six children and adolescents (31 male, 25 female)
diagnosed with active idiopathic nephrotic syndrome based
on the International Study of Kidney Disease in Children
[12] were enrolled in the study. Thirty patients with FSGS
and 26 patients with MCD were confirmed by kidney biop-
sy between March 2011 and April 2012 at the Department
of Pediatrics, Jinling Hospital, Nanjing, China. We selected
another 20 healthy, age- and sex-matched individuals (12
male, 8 female) as controls. Demographic and clinical data
(urinalysis, biochemical results, response to steroid, dura-
tion of disease, and current treatment) were obtained at the
time of enrollment. Patients with congenital nephrotic
syndrome, secondary nephrotic syndrome such as systemic
lupus erythematosus (SLE), and idiopathic nephrotic syn-
drome in remission status were excluded. Steroid-dependent
nephrotic syndrome (SDNS) was defined when a patient had
two consecutive relapses during corticosteroid therapy, or
within 14 days of ceasing therapy. Steroid-dependent nephrot-
ic syndrome (SRNS) was defined as no response to the initial
8 weeks of corticosteroid treatment. Blood samples obtained
from all participants were processed immediately. Serum
samples were separated by a 15-min centrifugation at
3,000 rpm and then stored at −70 °C until analysis.
Total RNA extraction and quantification
Total RNA was extracted from each serum sample (100 μl)
using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) in
accordance with the manufacturer’s protocols.
We used a TaqMan PCR kit (Applied Biosystems, Foster
City, CA, USA) to carry out assays following the manufac-
turer’s instructions. In brief, 2 μl of total RNA was reverse
transcribed to cDNA using a specific stem-loop RT primer
(Applied Biosystems) under the condition of 16 °C for
30 min, 42 °C for 30 min, and 85 °C for 5 min. RT–QPCR
was performed at 95 °C for 5min, followed by 40 cycles at
95 °C for 15 s and 60 °C for 1 min. The results were
analyzed on the ABI 7900 Real-Time PCR System (Applied
Biosystems). All reactions, including non-template controls,
were performed in triplicate. The calibration curves for
concentrations of the synthetic mature miR-192 and miR-
205 calibrators were linear from 102 to 105 fmol/l.
Assessment of interstitial fibrosis
Assessment of mesangial proliferation and interstitial fibro-
sis was determined on 4-μm paraffin-embedded sections
stained by periodic acid-Schiff stain (PAS). Ten microscopic
fields were viewed at magnification of 200× and scored
from 0 to 100 % for each patient. An experienced patholo-
gist blinded to the laboratory results evaluated the degree of
mesangial proliferation and interstitial fibrosis.
Statistics
Statistical analysis was performed with the software SPSS
17.0. The results were presented in mean±SD. Comparisons
were made using the ANOVA analysis followed by SNK
test for three parametric groups. Student’s t test was used for
two parametric groups. Chi-square test was used to examine
the differences in proportions between groups. Pearson cor-
relation coefficient (r) was used to test the relationship
between miRNAs and clinical parameters. All probabilities
were two-tailed. Statistical significance was determined by
p<0.05.
Results
The demographic and baseline data of participants are sum-
marized in Table 1. There was no significant difference in
age, sex, serum creatinine, urinary protein/creatinine ratio,
hepatic function, glomerular filtration rate (GFR), or dura-
tion of disease. The proportion of patients receiving distinct
therapies were similar (p=0.53), as well as that of the
patients’ response to the steroid at the time of enrollment
(p=0.83). The glomerular filtration rate was estimated using
the Schwartz formula [13].
Serum levels of miR-192 and miR-205
As compared to patients with MCD and healthy controls,
patients with FSGS had higher serum concentration of miR-
192 (324.49±42.74 fmol/l versus 90.19±27.14 fmol/l,
p<0.01, 324.49±42.74 fmol/l versus 44.81±26.03 fmol/l,
p<0.01, respectively) (Fig. 1a). Similarly, patients with
FSGS had higher serum concentration of miR-205 than
those with MCD and healthy controls (2.25±0.69 fmol/l
versus 0.60±0.51 fmol/l, p<0.01, 2.25±0.69 fmol/l versus
0.72±0.64 fmol/l, p<0.01, respectively), but there was no
difference between MCD and controls (0.60±0.51 fmol/l
versus 0.72±0.64 fmol/l, p>0.05) (Fig. 1b).
In the FSGS group, patients received calcineurin inhib-
itors or not had similar serum miRNAs levels (miR-192:
323.54±39.75 versus 327.60±54.94, p=0.83; 2.21±0.65
versus 2.39±0.85, p=0.56, respectively). The serum levels
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of miRNAs did not show any significant difference between
patients with distinct therapies within MCD group (miR-
192: 95.03±26.71 versus 79.29±26.49, p=0.18; 0.53±0.43
versus 0.77±0.64, p=0.35; respectively).
Relation with clinical parameters
Serum concentration levels of miR-192 and miR-205 had a
positive correlation with proteinuria in patients with FSGS
(miR-192: r=0.62, p<0.001; miR-205: r=0.54, p=0.002)
(Fig. 2a, b). The serum level of miR-192 was also correlated
with proteinuria in MCD (r=0.84, p<0.001) (Fig. 2c). There
was no significant relation between particular miRNA level
and other clinical parameters.
Relation with interstitial fibrosis
The degree of mesangial proliferation of FSGS was higher
that of MCD (35.2±12.3 % versus 16.2±5.6 %). There was
no correlation was found between the serum levels of the
miRNAs and the degree of mesangial proliferation in FSGS
and MCD. The percentage of interstitial fibrosis was
19.6±13.7 %. The degree of interstitial fibrosis was corre-
lated with serum level of miR-192 (r=0.342, p<0.05), but
no significant correlation with that of miR-205.
Discussion
FSGS and MCD have similar presentations but absolutely dif-
ferent outcomes. We use the responsiveness to steroids to ex-
trapolate the severity of renal histology, however the response
was nothing but a time-dependent and elementary way to es-
chew the confirmation of the exact pathology [14]. In addition,
the functional mode of steroids eliminating the proteinuria has
not been understood. In the present work, we analyzed the
serum miRNAs according to the definite histology including
MCD and FSGS rather than responsiveness to steroids.
Historically early FSGS often cannot be distinguished
from MCD, when it does not present with glomeruloscle-
rosis or interstitial fibrosis [15]. FSGS and MCD often have
heavy proteinuria, while renal fibrosis occurs in FSGS
Table 1 The demographic and baseline data of participants
Group FSGS MCD HC




Age 6.67±2.90 6.84±3.56 7.50±3.12
uPCR (mg/mg) 5.02±1.18 4.48±1.04
Serum creatinine(μmol/l) 41.13±15.61 38.90±24.63
ALT 22.10±4.66 24.00±5.12
AST 27.10±5.47 28.54±5.79












Student’s t test was used for two parametric groups. The Chi-square
test was used to examine the differences in proportions between groups
FSGS focal segmental glomerulosclerosis, MCD minimal change dis-
ease, HC healthy controls, GFR glomerular filtration rate, uPCR uri-
nary protein/creatinine ratio, CNI calcineurin inhibitors, ALT alanine
aminotransferase, AST aspartate aminotransferase, SRNS steroid-resis-
tant nephrotic syndrome, SDNS steroid-dependent nephrotic syndrome
Fig. 1 Comparison of serum concentrations of (a) miR-192 and (b)
miR-205 among patients with FSGS, MCD, and HC. Data were com-
pared by ANOVA analysis followed by SNK test. FSGS focal segmen-
tal glomerulosclerosis, MCD minimal change disease, HC healthy
controls
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predominantly, which indicates that other mechanisms ac-
celerating the process of fibrosis apart from proteinuria [16].
Many miRNAs have been found to play a pivotal role in the
physiology and pathogenesis of kidney disease [17, 18].
Tissue specificity and relative stability of miRNAs make
them promising candidates as biomarkers to reflect various
disease states. miR-192 and miR-205 have been reported in
multiple kidney diseases. In the current work, we found that
higher levels of serum miR-192 and miR-205 in FSGS
compared to that in MCD and healthy controls. miR-192
and miR-205 were positively correlated with proteinuria in
patients with FSGS. Results indicated that miR-192 level
positively correlated with the degree of renal fibrosis. Our
study was consistent with previous studies. Kato et al. [19]
showed that elevated miR-192 level in mouse mesangial cell
increased the expression of collagen contributing to matrix
accumulation and glomerulosclerosis. Kato et al. [20, 21]
also identified that increased miR-192 level could lead to
glomerulosclerosis in mesangial cell through TGF-β1 auto-
introduction and Akt activation. Additionally, Putta et al.
[22] found that suppression of miR-192 in diabetic mice
attenuated proteinuria and ameliorated renal fibrosis. Multi-
ple evidence has emerged that miR-192 and miR-205 par-
ticipated in the process of epithelial mesenchymal transition
(EMT) [23–26], which was proved to contribute to the renal
fibrosis [27–30].
This is an innovative study on analyzing the serum levels
of miR-192 and miR-205 in FSGS and MCD. There are
some inadequacies. First, the single-centre study limited the
sample size. Therefore we do not have enough statistical
evidence for a powerful conclusion. Second, the treatment
of each patient could be heterogenous, and the drugs they
were receiving might affect the results, especially the calci-
neurin inhibitors. In order to eliminate bias, we compared
the serum miRNAs levels between patients with or without
calcineurin inhibitors in each group. In each group, the
serum levels of miR-192 were similar between patients with
distinct treatment, as well as that of miR-205. Additionally,
we tested the miRNAs in serum without exploring the
cellular sources of them. Kato et al. showed that miR-192
were largely expressed in mesangial cells [20]. Further
studies are warranted to explore the underlying mechanism
to validate the hypothesis that circulating miRNAs play a
part in cell-to-cell communication [6].
In summary, our study, for the first time, showed that
serum miR-192 and miR-205 have higher expression
levels, which were correlated with the urine protein
and the degree of tubulointerstitial fibrosis in patients
with FSGS. The results suggest that miR-192 and miR-
205 have the potential as markers to differentiate FSGS
from MCD. The in-depth mechanism by which the miR-
192 and miR-205 accelerate the progressive process of
FSGS needs to be explored.
Fig. 2 Correlation between urinary protein and serum concentrations
of miR-192 (a), miR-205 in patients with FSGS (b), and miR-192 in
patients with MCD (c). Data were compared by Pearson correlation
coefficient (r). FSGS focal segmental glomerulosclerosis, MCD mini-
mal change disease
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